Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Droxidopa for Freezing of Gait in Parkinson's Disease
NCT01331122Phase 2Withdrawn
- Sponsor
- Chelsea Therapeutics International, Ltd.
- Start
- Apr 2012
- Primary completion
- Dec 2012
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of droxidopa in Freezing of gait (FOG) (2 arms), sponsored by Chelsea Therapeutics International, Ltd. Primary endpoint: Incidence, relatedness, and severity of adverse events at 18 weeks. Planned start Apr 2012; status: withdrawn.
02
Drugs
droxidopa
03
Conditions
Freezing of gait (FOG)
Beyond the preview
Go deeper on NCT01331122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01331122.